These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 23349390)

  • 21. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia.
    Bettelheim P; Valent P; Andreeff M; Tafuri A; Haimi J; Gorischek C; Muhm M; Sillaber C; Haas O; Vieder L
    Blood; 1991 Feb; 77(4):700-11. PubMed ID: 1993213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models.
    Lal D; Park JA; Demock K; Marinaro J; Perez AM; Lin MH; Tian L; Mashtare TJ; Murphy M; Prey J; Wetzler M; Fetterly GJ; Wang ES
    Mol Cancer Ther; 2010 Oct; 9(10):2737-51. PubMed ID: 20924124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
    Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renin angiotensin system genes are biomarkers for personalized treatment of acute myeloid leukemia with Doxorubicin as well as etoposide.
    Turk S; Turk C; Akbar MW; Kucukkaraduman B; Isbilen M; Demirkol Canli S; Malkan UY; Okay M; Ucar G; Sayinalp N; Haznedaroglu IC; Gure AO
    PLoS One; 2020; 15(11):e0242497. PubMed ID: 33237942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paradoxical effects of Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates on hCD45(+) cells in the bone marrow and spleen of leukemia-engrafted NOD/SCID or NRG mice.
    Bergstrom D; Leyton JV; Zereshkian A; Chan C; Cai Z; Reilly RM
    Nucl Med Biol; 2016 Oct; 43(10):635-41. PubMed ID: 27497632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Residual Disease in a Novel Xenograft Model of RUNX1-Mutated, Cytogenetically Normal Acute Myeloid Leukemia.
    Sivagnanalingam U; Balys M; Eberhardt A; Wang N; Myers JR; Ashton JM; Becker MW; Calvi LM; Mendler JH
    PLoS One; 2015; 10(7):e0132375. PubMed ID: 26177509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.
    Kelly KR; Nawrocki ST; Espitia CM; Zhang M; Yang JJ; Padmanabhan S; Ecsedy J; Giles FJ; Carew JS
    Int J Cancer; 2012 Dec; 131(11):2693-703. PubMed ID: 22488249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity.
    Cai S; Wang H; Bailey B; Ernstberger A; Juliar BE; Sinn AL; Chan RJ; Jones DR; Mayo LD; Baluyut AR; Goebel WS; Pollok KE
    Clin Cancer Res; 2011 Apr; 17(8):2195-206. PubMed ID: 21487065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
    Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ;
    Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice.
    Ailles LE; Gerhard B; Kawagoe H; Hogge DE
    Blood; 1999 Sep; 94(5):1761-72. PubMed ID: 10477702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
    Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
    J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia.
    McCormack E; Mujić M; Osdal T; Bruserud Ø; Gjertsen BT
    Blood; 2013 Feb; 121(7):e34-42. PubMed ID: 23243270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.
    Eriksson A; Chantzi E; Fryknäs M; Gullbo J; Nygren P; Gustafsson M; Höglund M; Larsson R
    Leuk Res; 2017 Dec; 63():41-46. PubMed ID: 29100024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models.
    DeRyckere D; Lee-Sherick AB; Huey MG; Hill AA; Tyner JW; Jacobsen KM; Page LS; Kirkpatrick GG; Eryildiz F; Montgomery SA; Zhang W; Wang X; Frye SV; Earp HS; Graham DK
    Clin Cancer Res; 2017 Mar; 23(6):1481-1492. PubMed ID: 27649555
    [No Abstract]   [Full Text] [Related]  

  • 35. Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo.
    Schnerch D; Schüler J; Follo M; Felthaus J; Wider D; Klingner K; Greil C; Duyster J; Engelhardt M; Wäsch R
    Oncotarget; 2017 Mar; 8(13):21153-21166. PubMed ID: 28416751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes.
    Sabnis HS; Minson KA; Monroe C; Allen K; Metts JL; Cooper TM; Woods WG; Castellino SM; Keller FG
    Leuk Res; 2020 Sep; 96():106421. PubMed ID: 32683126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.
    Powell JA; Lewis AC; Zhu W; Toubia J; Pitman MR; Wallington-Beddoe CT; Moretti PA; Iarossi D; Samaraweera SE; Cummings N; Ramshaw HS; Thomas D; Wei AH; Lopez AF; D'Andrea RJ; Lewis ID; Pitson SM
    Blood; 2017 Feb; 129(6):771-782. PubMed ID: 27956387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy.
    Cartel M; Mouchel PL; Gotanègre M; David L; Bertoli S; Mansat-De Mas V; Besson A; Sarry JE; Manenti S; Didier C
    Leukemia; 2021 Feb; 35(2):417-432. PubMed ID: 32447346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
    Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
    Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy.
    Maganti HB; Jrade H; Cafariello C; Manias Rothberg JL; Porter CJ; Yockell-Lelièvre J; Battaion HL; Khan ST; Howard JP; Li Y; Grzybowski AT; Sabri E; Ruthenburg AJ; Dilworth FJ; Perkins TJ; Sabloff M; Ito CY; Stanford WL
    Cancer Discov; 2018 Nov; 8(11):1376-1389. PubMed ID: 30115703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.